Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 18 de 18
Filter
1.
Eur Rev Med Pharmacol Sci ; 20(21): 4574-4580, 2016 11.
Article in English | MEDLINE | ID: mdl-27874938

ABSTRACT

OBJECTIVE: RANKL is a member of the TNF superfamily that stimulates chemokine release, monocyte/macrophage matrix migration and matrix metalloproteinase activity and plays an important role in atherosclerosis. In our study, we have evaluated whether RANKL gene polymorphisms are involved in ischemic stroke in Italian subjects. PATIENTS AND METHODS: In a retrospective study we have included 487 patients (242 males, 245 females) with history of ischemic stroke and 543 control subjects without history of ischemic stroke (277 males, 276 females). The rs9533156, and rs2277438 gene polymorphisms of the RANKL gene were analyzed by PCR and restriction fragment length polymorphism. RESULTS: We found that the rs9533156 gene polymorphism of the RANKL gene was significantly (55.0% versus 36.5%, p < 0.0001) and independently (adjusted OR 6.28 [2.34-4.21]) associated with history of ischemic stroke. No statistically significant difference was found between the two groups in our population for the rs2277438 gene polymorphism (p = 439). Furthermore, we have confirmed that rs 3134069, rs 2073617 and rs 2073618 polymorphisms of the OPG gene were significantly and independently associated with cerebrovascular disorders. CONCLUSIONS: The present study identifies, for the first time, the genetic variant of RANKL as an independent risk factor for ischemic stroke.


Subject(s)
Polymorphism, Single Nucleotide , Stroke/genetics , Female , Genetic Association Studies , Humans , Italy , Male , Osteoprotegerin/genetics , RANK Ligand/genetics , Retrospective Studies
2.
Eur Rev Med Pharmacol Sci ; 20(19): 4048-4054, 2016 10.
Article in English | MEDLINE | ID: mdl-27775794

ABSTRACT

OBJECTIVE: Fibroblast growth factor 23 (FGF23) was demonstrated to be involved in the occurrence and development of cardiovascular disease (CVD). The aim of this study was to investigate the potential role of FGF23 on presence and severity of peripheral arterial disease (PAD) in type 2 diabetic patients. PATIENTS AND METHODS: In this study, we analyzed FGF23 serum levels in 413 type 2 diabetic patients with PAD and in 598 diabetic controls without lower limbs atherosclerosis. RESULTS: We found that FGF23 median serum levels were significantly higher in patients than in diabetic controls (69.3 (58.8-75.1) pg/mL in PAD and 42.98 (37.1-49.8) pg/mL in subjects without PAD (p < 0.001) and were significantly and independently associated with critical limb ischemia (CLI) [OR, 7.69 (2.64-16.31); p = 0.001]. CONCLUSIONS: We have found, for the first time, that FGF23 could be associated with presence and severity of PAD in Italian patients with type 2 diabetes.


Subject(s)
Diabetes Mellitus, Type 2/complications , Fibroblast Growth Factors , Peripheral Arterial Disease/complications , Aged , Female , Fibroblast Growth Factor-23 , Humans , Ischemia/blood , Male , Risk Factors
3.
Article in English | MEDLINE | ID: mdl-26737992

ABSTRACT

Morphological analysis of the pulse wave of central blood pressure signal is commonly used for the study of cardiac and vascular properties, but very few attempts were performed for analyzing the peripheral pulse wave of blood flow. In this work, we analyzed this waveform using classical methods, based on the application of FFT, followed by principal components analysis, for assessing the properties of the blood flow. As a sample problem, we evaluated the capability of the proposed method of assessing the alterations correlated with the aging of the vascular system. Results show a good discrimination between the different age groups, confirming the validity of the approach.


Subject(s)
Laser-Doppler Flowmetry/methods , Microcirculation/physiology , Models, Cardiovascular , Adult , Age Factors , Aged , Aging/physiology , Cardiovascular Physiological Phenomena , Female , Fourier Analysis , Humans , Male , Middle Aged , Principal Component Analysis , Signal Processing, Computer-Assisted , Young Adult
4.
Nutr Metab Cardiovasc Dis ; 19(11): 751-9, 2009 Dec.
Article in English | MEDLINE | ID: mdl-19628379

ABSTRACT

The peroxisome proliferator-activated receptors (PPARs) are a group of three nuclear receptor isoforms, PPARalpha, PPARgamma and PPARdelta, encoded by different genes, and they form a subfamily of the nuclear receptor superfamily. The clinical interest in PPARs originates with fibrates and thiazolidinediones, which, respectively, act on PPARalpha and PPARgamma and are used to ameliorate hyperlipidaemia and hyperglycaemia in subjects with type 2 diabetes mellitus (T2DM). PPARs play a central role in these patients due to their ability to regulate the expression of numerous genes involved in glycaemic control, lipid metabolism, vascular tone and inflammation. Abnormal angiogenesis is implicated in several of the long-term complications of diabetes mellitus, characterized by vasculopathy associated with aberrant growth of new blood vessels. This pathological process plays a crucial role in diabetic retinopathy, nephropathy and neuropathy, impaired wound healing and impaired coronary collateral vessel development. In recent years, there has been increasing appreciation of the fact that PPARs might be involved in the molecular mechanisms that regulate angiogenesis through the action of growth factors and cytokines that stimulate migration, proliferation and survival of endothelial cells. During the last few years direct comparative analyses have been performed, using selective PPARs agonists, to clarify the angiogenic properties of the different members of the PPAR family. Lately, the findings provide new information to order to understand the biological, clinical and therapeutic effects of PPARs, and the role of these nuclear receptors in angiogenesis, with potentially important implications for the management of subjects affected by T2DM.


Subject(s)
Diabetes Mellitus, Type 2/metabolism , Diabetic Angiopathies/metabolism , Neovascularization, Pathologic/metabolism , Neovascularization, Physiologic , Peroxisome Proliferator-Activated Receptors/metabolism , Angiogenesis Inhibitors/therapeutic use , Animals , Diabetes Mellitus, Type 2/complications , Diabetes Mellitus, Type 2/drug therapy , Diabetes Mellitus, Type 2/physiopathology , Diabetic Angiopathies/drug therapy , Diabetic Angiopathies/etiology , Diabetic Angiopathies/physiopathology , Humans , Hypoglycemic Agents/therapeutic use , Ligands , Neovascularization, Pathologic/drug therapy , Neovascularization, Pathologic/physiopathology , Neovascularization, Physiologic/drug effects , Peroxisome Proliferator-Activated Receptors/drug effects , Signal Transduction
5.
Gene Ther ; 15(19): 1330-43, 2008 Oct.
Article in English | MEDLINE | ID: mdl-18633445

ABSTRACT

Local gene transfer of the human Lim mineralization protein (LMP), a novel intracellular positive regulator of the osteoblast differentiation program, can induce efficient bone formation in rodents. To develop a clinically relevant gene therapy approach to facilitate bone healing, we have used primary dermal fibroblasts transduced ex vivo with Ad.LMP-3 and seeded on a hydroxyapatite/collagen matrix prior to autologous implantation. Here, we demonstrate that genetically modified autologous dermal fibroblasts expressing Ad.LMP-3 are able to induce ectopic bone formation following implantation of the matrix into mouse triceps and paravertebral muscles. Moreover, implantation of the Ad.LMP-3-modified dermal fibroblasts into a rat mandibular bone critical size defect model results in efficient healing, as determined by X-rays, histology and three-dimensional microcomputed tomography (3DmuCT). These results demonstrate the effectiveness of the non-secreted intracellular osteogenic factor LMP-3 in inducing bone formation in vivo. Moreover, the utilization of autologous dermal fibroblasts implanted on a biomaterial represents a promising approach for possible future clinical applications aimed at inducing new bone formation.


Subject(s)
Bone Diseases/therapy , Fibroblasts/transplantation , Genetic Therapy/methods , Intracellular Signaling Peptides and Proteins/genetics , Osteogenesis/genetics , Transduction, Genetic/methods , Adaptor Proteins, Signal Transducing , Adenoviridae/genetics , Animals , Bone Diseases/diagnostic imaging , Bone Diseases/metabolism , Bone and Bones/diagnostic imaging , Bone and Bones/metabolism , Cytoskeletal Proteins , Fibroblasts/metabolism , Gene Expression , Genetic Vectors/administration & dosage , Genetic Vectors/genetics , Humans , Intracellular Signaling Peptides and Proteins/metabolism , LIM Domain Proteins , Male , Mice , Mice, Inbred C57BL , Models, Animal , Rats , Rats, Wistar , Reverse Transcriptase Polymerase Chain Reaction , Tissue Scaffolds , Tomography, X-Ray Computed , Transplantation, Autologous
6.
J Intern Med ; 262(1): 124-30, 2007 Jul.
Article in English | MEDLINE | ID: mdl-17598820

ABSTRACT

OBJECTIVES: Single nucleotide polymorphisms in genes encoding inflammatory molecules may determine genetic profiles associated with increased risk of development and progression of cardiovascular diseases. In this study, we evaluated distribution and reciprocal interaction of a set of functionally important polymorphisms of genes encoding prototypical inflammatory molecules in subjects with peripheral arterial occlusive disease (PAOD) and critical limb ischemia (CLI). We also investigated whether synergistic interactions between these pro-inflammatory gene polymorphisms influence the risk of PAOD and CLI. DESIGN, SUBJECTS AND METHODS: In a genetic association study that included 157 PAOD patients and 206 controls, the following gene polymorphisms were analysed: C-reactive protein (CRP) 1059 G/C, interleukin-6 (IL-6)-174 G/C, macrophage migration inhibitory factor (MIF)-173 G/C, monocyte chemoattractant protein (MCP-1) - 2518 A/G, E-selectin (E-Sel) Ser128Arg, intercellular adhesion molecule-1 (ICAM-1) 469 E/K, matrix metalloproteinase (MMP)-1 -1607 1G/2G, MMP-3-1171 5A/6A and MMP-9-1563 C/T. RESULTS: We found that IL-6, E-sel, ICAM-1, MCP-1, MMP-1 and MMP-3 gene polymorphisms were significantly and independently associated with PAOD. We also found that these pro-inflammatory polymorphisms determine genetic profiles that are associated with different levels of risk for PAOD and CLI, depending on the number of high-risk genotypes concomitantly carried by a given individual. CONCLUSIONS: Pro-inflammatory genetic profiles are significantly more common in subjects with PAOD. Synergistic effects between pro-inflammatory genotypes might be potential markers for the presence and severity of atherosclerotic disorders.


Subject(s)
Arterial Occlusive Diseases/genetics , Inflammation Mediators/physiology , Ischemia/genetics , Leg/blood supply , Peripheral Vascular Diseases/genetics , Aged , Aged, 80 and over , Case-Control Studies , Female , Genetic Predisposition to Disease , Genotype , Humans , Male , Polymorphism, Single Nucleotide , Severity of Illness Index
7.
Gut ; 56(9): 1248-56, 2007 Sep.
Article in English | MEDLINE | ID: mdl-17317789

ABSTRACT

BACKGROUND AND AIMS: Angiogenesis is a novel component in inflammatory bowel disease (IBD) pathogenesis. We have previously shown that immune-nonimmune interactions through the CD40-CD40-ligand (CD40L) pathway might sustain gut inflammation, although their effect on regulating inflammation-driven angiogenesis is unknown. The present study evaluated the role of the CD40-CD40L interaction in the promotion of immune-mediated angiogenesis in IBD. METHODS: Human nonimmune cells of colonic origin-namely, human intestinal fibroblasts (HIFs) and human intestinal microvascular endothelial cells (HIMECs)-were activated with either soluble CD40L (sCD40L), or CD40(+) D1.1 cells or CD40L-activated lamina propria T (LPT) cells before measuring pro-angiogenic cytokine release. Blocking antibodies to either CD40 or CD40L were used to disrupt the CD40-CD40L interaction. The dextran sodium sulphate (DSS) model of experimental colitis in CD40 and CD40L knockout mice was established to assess whether the CD40-CD40L pathway was implicated in controlling inflammation-driven angiogenesis in vivo. RESULTS: Engagement of CD40 on HIFs promoted the release of vascular endothelial growth factor (VEGF), interleukin-8 (IL-8) and hepatocyte growth factor (HGF). LPT cells were potent inducers of pro-angiogenic cytokine secretion by HIFs. Supernatants from sCD40L-activated HIFs induced migration of HIMECs and tubule formation, both of which were inhibited by blocking antibodies to either VEGF, IL-8 or HGF. Both CD40- and CD40L-deficient mice were protected from DSS-induced colitis and displayed a significant impairment of gut inflammation-driven angiogenesis, as assessed by microvascular density. CONCLUSIONS: The CD40-CD40L pathway appears to be crucially involved in regulating inflammation-driven angiogenesis, suggesting that strategies aimed at blocking CD40-CD40L interactions might be beneficial in acute and chronic intestinal injury.


Subject(s)
CD40 Antigens/immunology , CD40 Ligand/immunology , Inflammatory Bowel Diseases/immunology , Neovascularization, Pathologic/immunology , Animals , Cell Line , Cells, Cultured , Chemotaxis, Leukocyte/immunology , Colitis/immunology , Colon/immunology , Disease Models, Animal , Endothelial Cells/immunology , Fibroblasts/immunology , Hepatocyte Growth Factor/analysis , Humans , Interleukin-8/analysis , Intestinal Mucosa/blood supply , Intestinal Mucosa/immunology , Mice , Mice, Knockout , Vascular Endothelial Growth Factor A/analysis
8.
Acta Obstet Gynecol Scand ; 86(1): 99-101, 2007.
Article in English | MEDLINE | ID: mdl-17230297

ABSTRACT

BACKGROUND: Gadolinium derivatives are ionic paramagnetic contrast agents used to enhance magnetic resonance images, labeled as a pregnancy category C by the Food and Drug Administration because of a lack of epidemiological studies concerning first-trimester exposure. METHODS: Prospective cohort study to determine whether gadolinium derivatives exposure in periconceptional period is a risk factor for pregnancy or fetal development. RESULTS: We report the outcome of 26 pregnant women exposed to gadolinium derivatives in the first trimester without adverse effect on pregnancy and neonatal outcome. CONCLUSIONS: Currently, this study represents the only prospective investigation of gadolinium derivatives in pregnancy, but more data are necessary to exclude a teratogenic risk.


Subject(s)
Abnormalities, Drug-Induced/epidemiology , Contrast Media/toxicity , Gadolinium DTPA/toxicity , Gadolinium/toxicity , Teratogens/toxicity , Abnormalities, Drug-Induced/etiology , Adult , Cohort Studies , Female , Humans , Infant, Newborn , Italy/epidemiology , Magnetic Resonance Imaging/adverse effects , Maternal Exposure/adverse effects , Pregnancy , Pregnancy Outcome , Pregnancy Trimester, First , Prospective Studies
9.
Neurotoxicology ; 28(3): 696-7, 2007 May.
Article in English | MEDLINE | ID: mdl-17227680

ABSTRACT

Mitoxantrone is an antineoplastic agent considered a potential human teratogen because of its mechanism of action and is classified by the US Food and Drug Administration in pregnancy category risk D. In the literature there are only four cases of women exposed to the drug in late pregnancy. We report the first case of mitoxantrone therapy in the first trimester and during the pregnancy. A 41-year-old woman affected with multiple sclerosis, conceived during therapy and continued mitoxantrone until 29 weeks and 3 days of her pregnancy. She delivered by cesarean section at 39 weeks a growth restricted female baby weighing 1950g without evidence of congenital malformations.


Subject(s)
Analgesics/adverse effects , Fetal Growth Retardation/chemically induced , Mitoxantrone/adverse effects , Pregnancy Complications/chemically induced , Adult , Analgesics/therapeutic use , Apgar Score , Female , Fetal Growth Retardation/pathology , Humans , Magnetic Resonance Imaging , Mitoxantrone/therapeutic use , Multiple Sclerosis/complications , Multiple Sclerosis/drug therapy , Oligohydramnios/chemically induced , Oligohydramnios/pathology , Pregnancy , Pregnancy Complications/physiopathology , Pregnancy Trimester, First
10.
Reprod Toxicol ; 22(2): 227-33, 2006 Aug.
Article in English | MEDLINE | ID: mdl-16797917

ABSTRACT

Maternal thrombophilias increases the risk of an adverse pregnancy outcome. An extensive literature review highlights the role of inherited and acquired thrombophilic disorders in spontaneous abortion, both early and late, recurrent or isolate, in intrauterine growth retardation, in placenta abruption, in pre-eclampsia and in venous thromboembolism. We have particularly focused attention on the following factors: antithrombin III (ATIII), proteins C (PC) and S (PS) deficiencies, genetic mutations particularly factor V Leiden (FVL), prothrombin gene G20210A (PTM) and the thermolabile variant of the methylene tetrahydrofolate reductase C677T (MTHFR) gene, lupus anticoagulant (LAC) and anticardiolipin antibodies, VIIIc factor, hyperhomocysteinemia and acquired activated protein C resistance. Appropriate treatment can improve pregnancy outcome without teratogenic effects.


Subject(s)
Thrombophilia/complications , Thrombophilia/drug therapy , Abortion, Spontaneous/etiology , Abruptio Placentae/etiology , Anticoagulants/therapeutic use , Aspirin/therapeutic use , Female , Fetal Growth Retardation/etiology , Heparin/therapeutic use , Humans , Pre-Eclampsia/etiology , Pregnancy , Thrombophilia/congenital
11.
Reprod Toxicol ; 21(4): 390-8, 2006 May.
Article in English | MEDLINE | ID: mdl-16580940

ABSTRACT

Rubella is the first virus demonstrated as a teratogen. There is a high risk to develop congenital rubella syndrome (CRS) if the infection occurs in the first part of pregnancy, particularly in women without specific immunological protection. Specific therapies to prevent CRS are not available. Many developed countries have specific vaccination programs and maternal rubella is rare. However, in developing countries or where campaigns of rubella surveillance and preconceptional vaccination are inadequate, there are still cases of CRS registered despite primary possibilities of prevention. Maternal infection is not indicative of vertical transmission in 100% of cases, and damage does not necessarily occur in all cases of fetal infection. This is the reason why an adequate prenatal counselling is mandatory, particularly in cases of proven maternal infection. Advanced prenatal diagnostic techniques, invasive or not, should be offered to the women especially in order to distinguish the cases without fetal damage. Prevention of voluntary interruption of pregnancy for the latter or in case of maternal false IgM rubella antibody positivity or IgM "chronic carrier" patients is mandatory. World wide, the aim is to perform an adequate primary prevention through vaccination of childbearing age women without specific immunological protection.


Subject(s)
Pregnancy Complications, Infectious , Rubella , Female , Fetal Diseases/diagnosis , Fetal Diseases/immunology , Fetal Diseases/prevention & control , Humans , Infant, Newborn , Pregnancy , Pregnancy Complications, Infectious/diagnosis , Pregnancy Complications, Infectious/epidemiology , Pregnancy Complications, Infectious/immunology , Prenatal Care , Rubella/complications , Rubella/congenital , Rubella/diagnosis , Rubella/epidemiology , Rubella/immunology , Rubella/prevention & control , Rubella Vaccine/immunology , Rubella virus/immunology , Rubella virus/isolation & purification , Vaccination
12.
Minerva Ginecol ; 58(2): 91-9, 2006 Apr.
Article in English | MEDLINE | ID: mdl-16582865

ABSTRACT

AIM: Many women exposed to completely innocuous agents during pregnancy have a high perception of adverse effects to such an extent that they may interrupt their pregnancy. The objective of our study is to evaluate the importance of the perception of the risk level in making the decision to end the pregnancy and the relevance that a teratology consultation can have in preventing unmotivated terminations of pregnancy METHODS: We carried out a survey on 350 women in Rome who voluntarily interrupted their pregnancy to evaluate the prevalence due to presumed teratogen. Contemporarily we studied the pregnancy outcomes, the clinical, the psychological and the socio-economic factors of 142 women who contacted our Teratology Information Service (TIS) in the 1(st)trimester of pregnancy because suspected of teratogen exposure: 72 decided to terminate their pregnancy, whereas 70 were used as a control group. RESULTS: On 350 women who voluntarily interrupted their pregnancy, 4 cases (1.4%) reported exposure to a suspected teratogen, but our evaluation determined only 1 case. On 72 women decided to terminate their pregnancy and who contacted our TIS, after counselling 73% continued their pregnancy with respect to 97% of the control group. Those women who interrupted their pregnancy did so because of personal reasons independently to or the type of exposure or the risk attributed by us. CONCLUSIONS: From our data it appears that a percentage of voluntary abortions is related to suspected teratogen exposure and that TIS are effective in the prevention of this kind of voluntary abortions caused by groundless fears.


Subject(s)
Abnormalities, Drug-Induced , Abortion, Induced/statistics & numerical data , Adult , Female , Follow-Up Studies , Humans , Retrospective Studies , Risk Assessment , Risk Factors , Surveys and Questionnaires , Teratogens
13.
Reprod Toxicol ; 20(3): 323-9, 2005.
Article in English | MEDLINE | ID: mdl-15925481

ABSTRACT

The present paper is a review of the data available in the literature concerning the prenatal exposure to radiation evaluating the reported teratogenic effect. We have particularly focused on the fetal effects of maternal ionising radiation exposure, both diagnostic and occupational, particularly in terms of congenital anomalies and birth weight. Ionising radiation represents a possible teratogen for the fetus, but this risk has been found to be dependent on the dosage and the effects correlatable to the gestational age at exposure. Recently, of particularly note is the fact that maternal thyroid exposure to diagnostic radiation has been associated with a slight reduction in the birth weight. Inadvertent exposure from diagnostic procedures in pregnancy doesn't usually increase the natural risk of congenital anomalies but creates a considerable state of maternal anxiety. Diagnostic radiological procedures should be avoided in pregnant women unless the information cannot be obtained by other techniques.


Subject(s)
Abnormalities, Radiation-Induced , Maternal Exposure/adverse effects , Prenatal Exposure Delayed Effects , Adult , Animals , Birth Weight/radiation effects , Dose-Response Relationship, Radiation , Female , Humans , Occupational Exposure/adverse effects , Pregnancy , Radiation Dosage , Radioactive Hazard Release , Radiography/adverse effects
16.
Drug Saf ; 24(12): 889-901, 2001.
Article in English | MEDLINE | ID: mdl-11735646

ABSTRACT

Approximately 1% of congenital anomalies relate to pharmacological exposure and are. in theory, preventable. Prevention consists of controlled administration of drugs known to have teratogenic properties (e.g. retinoids, thalidomide). When possible, prevention could take the form of the use of alternative pharmacological therapies during the pre-conception period for certain specific pathologies, selecting the most appropriate agent for use during pregnancy [e.g. haloperidol or a tricyclic antidepressant instead of lithium; anticonvulsant drug monotherapy in place of multitherapy; propylthiouracil instead of thiamazole (methimazole)], and substitution with the most suitable therapy during pregnancy (e.g. insulin in place of oral antidiabetics; heparin in place of oral anticoagulants; alpha-methyldopa instead of ACE inhibitors). Another strategy is the administration of drugs during pregnancy taking into account the pharmacological effects in relation to the gestation period (e.g. avoidance of chemotherapy during the first trimester, avoidance of nonsteroidal anti-inflammatory drugs in the third trimester, and avoidance of high doses of benzodiazepines in the period imminent to prepartum).


Subject(s)
Anticonvulsants/adverse effects , Antidepressive Agents/adverse effects , Congenital Abnormalities/etiology , Retinoids/adverse effects , Teratogens , Anti-Inflammatory Agents, Non-Steroidal/adverse effects , Congenital Abnormalities/prevention & control , Female , Humans , Pregnancy
17.
Clin Immunol ; 90(1): 115-8, 1999 Jan.
Article in English | MEDLINE | ID: mdl-9884359

ABSTRACT

This study aims at observing and comparing the antigen expression of some fetal T- and B-lymphocyte subpopulations in Rh-isoimmunization, which determines anemic hypoxia in the fetus, and nonimmune fetal hydrops (NIFH) which, even if there are some etiological factors involved, causes hipoxic hypoxia in the fetus. Twelve fetuses were studied by way of 30 fetal blood samples obtained by ultrasound-guided cordocentesis between the 20th and 36th gestational week. Twenty-four blood samples in all where taken from the eight fetuses with Rh-isoimmunization. Six blood samples were obtained from the four fetuses with NIFH. The lymphocyte phenotypes studied by monoclonal antibodies and flow cytometry were the following: CD3, CD4, CD8, expression of T-lymphocyte subpopulations; BsIg, CD19, expression of B-lymphocyte subpopulations. We observed a near-normal maturation process in fetuses with Rh isoimmunization, whereas in fetuses with NIFH we observed inhibition and/or delayed expression of T-lymphocytes. An early and increased B-lymphocyte activation marked a cooperation between the two systems in the early gestational periods.


Subject(s)
Fetus/immunology , Hydrops Fetalis/immunology , Immune System/embryology , Rh Isoimmunization/immunology , Anemia/immunology , Antigens, CD/biosynthesis , Antigens, CD/blood , B-Lymphocytes/immunology , B-Lymphocytes/metabolism , Female , Fetal Blood/immunology , Fetal Hypoxia/immunology , Humans , Hydrops Fetalis/etiology , Lymphocyte Subsets , Pregnancy , T-Lymphocytes/immunology , T-Lymphocytes/metabolism
18.
Minerva Ginecol ; 51(10): 385-91, 1999 Oct.
Article in Italian | MEDLINE | ID: mdl-10638164

ABSTRACT

BACKGROUND: Coenzyme Q10 (ubidecarenone) is a torpeniod molecule mainly located in bacterial and mitochondrial membranes. It is a part of a specific enzyme system and acts primarily on the transport of electrons in the mitochondrial respiratory chain. It performs an antioxidant action. We studied both fetal and maternal coenzyme Q10 plasma levels in physiological conditions and also in the presence of some pathologies. METHODS: As regards the maternal side, we selected 483 pregnancies, performing 615 blood samples, and divided them into four groups: A: physiological pregnancies; B: spontaneous abortions; C: threatened abortions; D: threatened late abortions and threatened pre-term deliveries. We then selected 61 pregnancies which differed from the previous ones and determined Q10 levels in fetal samples obtained by cordocentesis. We divided a control group from pathological groups: intra-uterine growth retardation (IUGR); Rh-isoimmunization (with intra-uterine transfusion), non immune fetal hydrops, fetal malformations. Coenzyme Q10 levels were determined in only one laboratory by high-performance liquid chromatography (HPLC). Coenzyme Q10 concentrations were expressed as mg/ml, the data as the mean + SD. Statistical analysis was performed employing a linear regression model and the student "t"-test. RESULTS: After working out a normality curve of CoQ10 levels in maternal blood, we noticed that the levels of Coenzyme Q10 were low in spontaneous abortions, in threatened late abortions and in threatened pre-term deliveries. We determined the value of 0.3 mg/ml as a cutoff to differentiate the fetal from the adult values. Moreover, CoQ10 values turned out to be increased only in fetuses affected by non-immune fetal hydrops. CONCLUSIONS: Accordingly, we can say that maternal CoQ10 plasma levels can be considered as a marker of pathological uterine contractile activity. There is a substantial increase in CoQ10 fetal plasma levels in fetuses affected by hypoxic hypoxia and also in those affected by non-immune fetal hydrops.


Subject(s)
Abortion, Spontaneous/blood , Abortion, Threatened/blood , Antioxidants/analysis , Fetal Blood/chemistry , Fetal Diseases/blood , Ubiquinone/analogs & derivatives , Abortion, Spontaneous/diagnosis , Abortion, Threatened/diagnosis , Adult , Coenzymes , Diagnosis, Differential , Female , Fetal Diseases/diagnosis , Fetal Growth Retardation/blood , Humans , Linear Models , Obstetric Labor, Premature , Pregnancy , Ubiquinone/blood
SELECTION OF CITATIONS
SEARCH DETAIL
...